NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Stock Forecast, Price & News

$3.98

-0.12 (-2.93%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $3.93
▼
$4.09
50-Day Range: $3.25
▼
$4.40
52-Week Range: $3.10
▼
$9.85

Volume: 147,000 shs
Average Volume: 139,194 shs
Market Capitalization: $132.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.00

Milestone Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 377.4% Upside
$19.00 Price Target
Short Interest: Healthy
3.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.16
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.54) to ($1.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

641st out of 1,010 stocks

Pharmaceutical Preparations Industry

321st out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Milestone Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.00, Milestone Pharmaceuticals has a forecasted upside of 377.4% from its current price of $3.98.
Amount of Analyst Coverage
Milestone Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.06% of the outstanding shares of Milestone Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Milestone Pharmaceuticals has recently decreased by 2.86%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Milestone Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Milestone Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MIST.

2.9

News and Social Media Coverage

News Sentiment
Milestone Pharmaceuticals has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Milestone Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.12% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
73.84% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.54) to ($1.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Milestone Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Milestone Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Milestone Pharmaceuticals has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIST Stock News Headlines

May 23, 2023 | markets.businessinsider.com

Expert Ratings for Milestone Pharmaceuticals

May 22, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

May 29, 2023 | Behind the Markets (Ad)

[BREAKING] Pentagon to Spend Billions on "Living Missile"

Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!

May 19, 2023 | americanbankingnews.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected to Earn Q2 2023 Earnings of ($0.37) Per Share

May 18, 2023 | americanbankingnews.com

HC Wainwright Research Analysts Decrease Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Milestone Pharmaceuticals (MIST) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)

May 12, 2023 | msn.com

Milestone Pharmaceuticals: Q1 Earnings Insights

May 29, 2023 | Behind the Markets (Ad)

[BREAKING] Pentagon to Spend Billions on "Living Missile"

May 11, 2023 | finanznachrichten.de

Milestone Pharmaceuticals, Inc.: Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

May 11, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

May 8, 2023 | finance.yahoo.com

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

May 1, 2023 | finance.yahoo.com

Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares

April 21, 2023 | msn.com

Unusual Call Option Trade in Milestone Pharmaceuticals (MIST) Worth $14.46K

April 21, 2023 | finance.yahoo.com

Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years

April 16, 2023 | americanbankingnews.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Forecasted to Post Q1 2023 Earnings of ($0.38) Per Share

April 13, 2023 | nasdaq.com

Oppenheimer Maintains Milestone Pharmaceuticals (MIST) Outperform Recommendation

April 12, 2023 | finance.yahoo.com

Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023 | americanbankingnews.com

Oppenheimer Lowers Milestone Pharmaceuticals (NASDAQ:MIST) Price Target to $13.00

April 4, 2023 | americanbankingnews.com

HC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

April 3, 2023 | americanbankingnews.com

Milestone Pharmaceuticals (NASDAQ:MIST) Rating Reiterated by HC Wainwright

April 2, 2023 | americanbankingnews.com

FY2026 EPS Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Increased by Analyst

March 31, 2023 | finance.yahoo.com

Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year

March 30, 2023 | msn.com

Milestone Pharmaceuticals's Return On Capital Employed Overview

March 29, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

March 29, 2023 | benzinga.com

Milestone Pharmaceuticals Stock (NASDAQ:MIST), Guidance and Forecast

March 28, 2023 | finance.yahoo.com

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIST Company Calendar

Last Earnings: 3/29/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MIST
CUSIP: N/A
CIK: 1408443
Web: www.milestonepharma.com
Phone: (514) 336-0444
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +377.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,390,000.00
Net Margins: N/A
Pretax Margin: -988.85%
Return on Equity: -83.54%
Return on Assets: -65.44%

Debt

Debt-to-Equity Ratio: 0.88
Current Ratio: 13.63
Quick Ratio: 13.63

Sales & Book Value

Annual Sales: $5 million
Price / Sales: 26.55
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.94 per share
Price / Book: 2.05

Miscellaneous

Outstanding Shares: 33,360,000
Free Float: 29,982,000
Market Cap: $132.77 million
Optionable: Not Optionable
Beta: 2.02

Key Executives

Joseph G. Oliveto
President, Chief Executive Officer & Director

Jeff Nelson
Chief Operating Officer

Amit Hasija
CFO & Executive VP-Corporate Development

Debbie K. Everidge
Vice President-Information Technology

David B. Bharucha
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MIST Stock - Frequently Asked Questions

Should I buy or sell Milestone Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MIST shares.
View MIST analyst ratings or view top-rated stocks.
What is Milestone Pharmaceuticals' stock price forecast for 2023?: 2 analysts have issued 12 month target prices for Milestone Pharmaceuticals' stock. Their MIST share price forecasts range from $13.00 to $25.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 377.4% from the stock's current price.
View analysts price targets for MIST or view top-rated stocks among Wall Street analysts.
How have MIST shares performed in 2023?: Milestone Pharmaceuticals' stock was trading at $3.96 at the start of the year. Since then, MIST shares have increased by 0.5% and is now trading at $3.98.
View the best growth stocks for 2023 here.
When is Milestone Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our MIST earnings forecast.
How were Milestone Pharmaceuticals' earnings last quarter?: Milestone Pharmaceuticals Inc. (NASDAQ:MIST) issued its earnings results on Wednesday, March, 29th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.04. The business had revenue of $3.50 million for the quarter, compared to analysts' expectations of $3.50 million.
What ETFs hold Milestone Pharmaceuticals' stock?: ETFs with the largest weight of Milestone Pharmaceuticals (NASDAQ:MIST) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Milestone Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).
When did Milestone Pharmaceuticals IPO?: (MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
What is Milestone Pharmaceuticals' stock symbol?: Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."
Who are Milestone Pharmaceuticals' major shareholders?: Milestone Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include RTW Investments LP (9.78%), BlackRock Inc. (6.23%), Alta Fundamental Advisers LLC (2.70%), Barclays PLC (2.54%), JPMorgan Chase & Co. (1.13%) and BML Capital Management LLC (0.66%). Insiders that own company stock include David Bharucha, De Solidarite Des Travai Fonds, Debra K Liebert, Paul F Truex, Robert James Wills and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Milestone Pharmaceuticals?: Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Milestone Pharmaceuticals' stock price today?: One share of MIST stock can currently be purchased for approximately $3.98.
How much money does Milestone Pharmaceuticals make?: Milestone Pharmaceuticals (NASDAQ:MIST) has a market capitalization of $132.77 million and generates $5 million in revenue each year. The company earns $-58,390,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.
How can I contact Milestone Pharmaceuticals?: Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The official website for the company is www.milestonepharma.com. The company can be reached via phone at (514) 336-0444 or via email at ir@milestonepharma.com.

This page (NASDAQ:MIST) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial